PET imaging and in silico analyses to support personalized treatment in oncology

Moek, K., 2020, [Groningen]: Rijksuniversiteit Groningen. 201 p.

Research output: ThesisThesis fully internal (DIV)

Copy link to clipboard


  • Title and contents

    Final publisher's version, 536 KB, PDF document

  • Chapter 1

    Final publisher's version, 528 KB, PDF document

  • Chapter 2

    Final publisher's version, 1.26 MB, PDF document

  • Chapter 3

    Final publisher's version, 874 KB, PDF document

    Embargo ends: 24/02/2021

    Request copy

  • Chapter 4

    Final publisher's version, 2.01 MB, PDF document

  • Chapter 5

    Final publisher's version, 1.38 MB, PDF document

  • Chapter 6

    Final publisher's version, 1.6 MB, PDF document

  • Chapter 7

    Final publisher's version, 582 KB, PDF document

  • Chapter 8

    Final publisher's version, 503 KB, PDF document

  • Chapter 9

    Final publisher's version, 509 KB, PDF document

  • Complete thesis

    Final publisher's version, 5.03 MB, PDF document

    Embargo ends: 24/02/2021

    Request copy

  • Propositions

    Final publisher's version, 452 KB, PDF document


Over the last decades many molecules and key pathways in cancer were identified, which facilitated a shift in anticancer drug development from DNA-damaging chemotherapy to a more personalized approach with targeted antibody therapeutics including antibody-drug conjugates (ADC) and bispecific T-cell engagers (BiTEs). A major challenge in oncology is to identify those patients that will benefit from targeted antibody therapeutics. Eventually this should lead to ‘personalized medicine’ in which a specific drug is used to treat a tumor with specific molecular or genetic characteristics in a specifically selected patient. Therefore, it is important to assess tumor selective expression of molecular targets, which is usually done by immunohistochemistry (IHC), but there may also be a role for molecular PET imaging in selecting patients and predicting tumor responses. This thesis provides an overview of molecular PET imaging with antibodies in cancer patients. Moreover, results from a first-in-human PET study using a BiTE as tracer were published. With a plethora of targeted agents becoming available to treat patients with cancer, broad knowledge concerning frequency of target expression across tumor types is of importance to fully exploit therapeutic options. Performing large-scale, golden standard, IHC analyses for many drug targets is time-consuming and demands many resources. Therefore we used functional genomic mRNA profiling instead to predict target overexpression rates for the proteoglycan “glypican 3” and for 59 ADC targets across 60 tumor types and subtypes.
Original languageEnglish
QualificationDoctor of Philosophy
Awarding Institution
Award date24-Feb-2020
Place of Publication[Groningen]
Print ISBNs978-94-034-2388-3
Electronic ISBNs978-94-034-2389-0
Publication statusPublished - 2020

Download statistics

No data available

ID: 112978295